Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
-4.55%
1 month
5%
YTD
-19.23%
1 year
-16%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Industrials
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
24 July 24 |
First patient dosed in Phase 2a IBS trial at Mass General
×
First patient dosed in Phase 2a IBS trial at Mass General |
22 July 24 |
Notification of cessation of securities - TYP
×
Notification of cessation of securities - TYP |
10 July 24 |
Phase 2a Fibromyalgia clinical study completed at U-M
×
Phase 2a Fibromyalgia clinical study completed at U-M |
01 July 24 |
Maiden dosing of TRP-8803 completed in global first
×
Maiden dosing of TRP-8803 completed in global first |
26 June 24 |
Dr Robin Carhart-Harris renews role as SAB Chair
×
Dr Robin Carhart-Harris renews role as SAB Chair |
19 June 24 |
Appointment product registration & reimbursement strategy
×
Appointment product registration & reimbursement strategy |
17 June 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
07 June 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
07 June 24 |
Details of Company Address
×
Details of Company Address |
06 June 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
04 June 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
31 May 24 |
Change of Director's Interest Notice - JC
×
Change of Director's Interest Notice - JC |
31 May 24 |
Upcoming Expiry of Options
×
Upcoming Expiry of Options |
29 May 24 |
Reinstatement to Quotation
×
Reinstatement to Quotation |
29 May 24 |
Investor Presentation May 2024 Precision Psychedelic Therapy
×
Investor Presentation May 2024 Precision Psychedelic Therapy |
29 May 24 |
Tryptamine Therapeutics Limited commences trading on the ASX
×
Tryptamine Therapeutics Limited commences trading on the ASX |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.